Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
Cyclo Therapeutics, Inc. goes for Phase 2b Study of Trappsol® Cyclo™ for treating early Alzheimer’s disease.
See full post…
Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease
Great paper on the relations of Gal-3 levels and Aβ deposits and tau aggregates in #brain tissue in #alzheimersdisease published by a great collaboration of the University of Seville, ENS-PSL, EHESS, Université Paris Cité, Lund University, and the University of Gothenburg.
#neurodegenerativediseases #alzheimers #brainhealth #carbohydrates #glycotime